Report Back From SABCS 2024: What’s the Latest in MBC
Welcome to our Season 10 opening episode! Today we’re discussing some of the big updates in metastatic breast cancer research from the 2024 San Antonio Breast Cancer Symposium (SABCS). Joining us today is Dr. Debu Tripathy, breast oncologist at The University of Texas MD Anderson Cancer Center who will break down into understandable terms some of the most impactful findings shared at SABCS, from advances in endocrine therapy and HER2-targeted treatments to exciting developments in PI3K inhibition and nausea control.
Meet the Guest of the Episode
Debu Tripathy, MD
Dr. Tripathy is Professor of Medicine and Chair, Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. He received a degree in Chemical Engineering from the Massachusetts Institute of Technology and completed medical school and an internal medicine residency at Duke University followed by a Hematology/Oncology fellowship at the University of California at San Francisco. His clinical research focuses on the evaluation and development of novel therapeutics in breast cancer, specifically, those targeting sensitivity and resistance mechanisms to growth factors endocrine modulators and cell cycle control pathways as well as biomarkers that predict sensitivity and resistance. He has led clinical trials that have supported the approval of new biological therapies for breast cancer that target the HER2 oncogene and cyclin-dependent kinases, both of which have improved patient survival. Dr. Tripathy has published numerous original translational and landmark clinical research articles in the area of breast cancer and serves on several editorial boards, study sections, and societies as well as Editor-in-Chief of CURE Magazine. He has previously served as President of the American Society of Breast Disease and of the Society of Integrative Oncology.
